New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome.

about

New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome.

Item

http://www.wikidata.org/entity/Q51249475

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

New Peptidomimetic Boronates f ...... ctivity of the 26S Proteasome.

@en

New Peptidomimetic Boronates f ...... ctivity of the 26S Proteasome.

@nl

type

Item

label

New Peptidomimetic Boronates f ...... ctivity of the 26S Proteasome.

@en

New Peptidomimetic Boronates f ...... ctivity of the 26S Proteasome.

@nl

prefLabel

New Peptidomimetic Boronates f ...... ctivity of the 26S Proteasome.

@en

New Peptidomimetic Boronates f ...... ctivity of the 26S Proteasome.

@nl

P1476

New Peptidomimetic Boronates f ...... ctivity of the 26S Proteasome.

@en

P2093

Alaknanda Adwal

http://www.w3.org/2001/XMLSchema#string

Andrew D Abell

http://www.w3.org/2001/XMLSchema#string

Andrew G Turner

http://www.w3.org/2001/XMLSchema#string

David F Callen

http://www.w3.org/2001/XMLSchema#string

Xiaozhou Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Macrocyclic protease inhibitors with reduced peptide character

On the size of the active site in proteases. I. Papain

Chemistry in living systems

The resistance mechanisms of proteasome inhibitor bortezomib.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

20S proteasome and its inhibitors: crystallographic knowledge for drug development.

Development of proteasome inhibitors in oncology and autoimmune diseases.

Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).

P304

1039-1043

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSMEDCHEMLETT.6B00217

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27994734

http://www.w3.org/2001/XMLSchema#string

P932

5150673

http://www.w3.org/2001/XMLSchema#string